Status and phase
Conditions
Treatments
About
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
Full description
RESOLVE is a pragmatic, cluster-randomised, open-label study designed to evaluate in real-world conditions the comparative effectiveness of two default dialysate sodium concentrations.
Dialysis sites will be randomised in a 1:1 ratio to a default dialysate sodium concentration of 137mmol/l or 140mmol/l. 'Default' is defined as the use of the allocated dialysate sodium for ≥ 90% of delivered dialysis sessions in the unit. All other care will be according to standard local practices as determined by the site.
Outcomes will be assessed on individual patients dialysing at those sites. Sites will be asked to consent to participation while waiver or opt-out consent will be sought for individual patients.
It is anticipated that site accrual will occur over 5-7 years with average study duration expected to be approximately 2-5 years. The actual length of the study will be end-point determined.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
The site inclusion criteria are:
The exclusion criteria are:
Primary purpose
Allocation
Interventional model
Masking
50,000 participants in 2 patient groups
Loading...
Central trial contact
Grace Balicki; Erika Dempsey
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal